Background: Success and event rates of endoscopic ultrasound (EUS)-guided biliary drainage vary with techniques, and results from different studies remain inconsistent. Objective: We conducted a proportion meta-analysis to evaluate the efficacy and safety of EUS-guided biliary drainage and compare the outcomes of current procedures. Methods: We searched MEDLINE, Embase, Cochrane and Web of knowledge to identify studies reporting technical success, clinical success and complication rates of EUS-guided biliary drainage techniques to estimate their clinical and technical efficacy and safety. Results: We identified 17 studies including a total of 686 patients. The overall clinical success and technical success rates were respectively 84% confidence interval (CI) 95% (80-88) and 96% CI 95% (93-98) for hepaticogastrostomy, and respectively 87% CI 95% (82-91) and 95% CI 95 (91-97) for choledochoduodenostomy. Reported adverse event rates were significantly higher (p ¼ 0.01) for hepaticogastrostomy (29% CI 95% (24-34)) compared to choledochoduodenostomy (20% CI 95% (16-25)). Compared with hepaticogastrostomy, the pooled odds ratio for the complication rate of choledochoduodenostomy was 2.01 (1.25; 3.24) (p ¼ 0.0042), suggesting that choledochoduodenostomy might be safer than hepaticogastrostomy.
Introduction
Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a transpapillary stent is the standard procedure for biliary decompression because of its high efficacy and low morbidity. 1 Even when performed by an expert, however, ERCP-based deobstruction and stenting fails in 5% for one or several reasons. In these cases, standard alternative approaches include surgical bypass and percutaneous transhepatic cholangiography and biliary drainage (PTBD). However, these procedures are associated with higher patient discomfort and prolonged hospital stay.
2 PTBD can also require long-term exchanges of indwelling drains, a major source of discomfort for patients receiving palliative care. 3 Surgical biliary decompression is associated with morbidity ranging from 9% to 67% and mortality up to 3% in the postoperative period. [4] [5] [6] [7] Endoscopic ultrasound-guided biliary drainage (EUBD) is a recently developed alternative to PTBD for patients in whom ERCP has failed. There are many reports regarding the safety, feasibility and clinical efficacy of EUBD. EUBD includes transenteric techniques, so-called EUS-guided choledochoduodenostomy (CDS) and EUS-guided hepaticogastrostomy (HGS), and anatomic or ''natural'' techniques, i.e. EUS-guided rendezvous (RDV) and EUS antegrade transpapillary drainage (AG). The transhepatic and extrahepatic approaches are different with respect to indications, techniques and complications, although many reports have analyzed the combined results of their case-mix including both intrahepatic and extrahepatic approaches. In the extrahepatic approach, the common bile duct is accessed mainly through the duodenum. Biliary drainage can therefore be achieved using either transluminal stent placement (choledochoduodenostomy) or transpapillary stent placement via the RDV technique, whereas in the intrahepatic approach, the left lobe of the liver is accessed from the upper gastric wall and more rarely from the distal esophagus or jejunum. Using this approach, biliary drainage can be achieved using either transluminal stent placement (hepaticogastrostomy) or transpapillary stent placement via the RDV technique or AG technique. 8 Published studies have reported variable success rates and adverse events using EUS-guided biliary drainage techniques. In this study, we aimed to evaluate the clinical efficacy, technical efficacy and safety of EUBD transenteric approaches, i.e. choledochoduodenostomy and hepaticogastrostomy, whose technical principles are illustrated in Figure 1 .
Methods

Data sources and search strategy
The systematic review was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines 9 and MetaAnalysis of Observational Studies in Epidemiology guidelines. 10 PubMed, Web of Knowledge, Embase and Cochrane library were searched from January 2000 to January 2018. Animal and review studies were excluded. The following Medical Subject Headings, Emtree and keyword search terms were used in combination: biliary drainage, biliary stent, transpapillary biliary drainage, transluminal biliary drainage, choledochoduodenostomy, hepaticogastrostomy, endoscopic ultrasound guided, EUBD, EUS-guided biliary drainage, therapeutic EUS, endoscopic anterograde cholangiography, and interventional EUS. Published abstracts or unpublished data were not included.
Study selection and data extraction
All titles and abstracts of papers retrieved in the prespecified search were screened by two reviewers (A.H., A.S.). Titles and abstracts were screened independently based on the eligibility criteria. Disagreement between two reviewers was discussed with a third reviewer (F.P.). We included EUBD achieved with either CDS or HGS. Studies were included if they reported technical success, clinical success and adverse events. Studies were excluded if one of the latter items was missing. Studies reporting patients with duodenal stents or including fewer than 15 patients were excluded to prevent bias. 11 Non-English language studies were excluded from this systematic review and meta-analysis as well as those with overlapping patients or performed in community hospitals. Extracted data included authors' names, year of publication, study design, patient demographics, causes of biliary obstruction, EUS puncture route, method of biliary drainage, technical success, clinical success and details of adverse events. Primary outcome was clinical success. We also excluded studies evaluating techniques other than CDS or HGS to avoid heterogeneity.
Statistical analysis
The primary outcome measure in this study was efficacy of EUBD as assessed by clinical success rate. Technical success rate and safety were secondary outcome measures. Weighted pooled rates were calculated for the primary outcomes of interest with corresponding 95% confidence intervals (CI). These were analyzed using the random-effects model (DerSimonian-Laird method). 12 Heterogeneity across studies was assessed using the Cochran Q test and I 2 statistics. A p value of < 0.1 for Cochran Q test was defined as indicating the presence of heterogeneity. 13 I 2 , unlike Q, does not inherently depend on the number of studies considered, with values of 25%, 50% and 75% taken to indicate low, moderate and high levels of heterogeneity, respectively. Possible publication bias or other small study effects were disclosed using the Egger test. 14 We did not conduct further statistical tests for funnel plot asymmetry because of the limited test power when fewer than 10 studies are included. 11 In all cases, p < 0.05 was considered statistically significant. Descriptive data are presented as counts and percentages for categorical variables and mean (standard deviation (SD)) or median (interquartile range (IQR)) for continuous variables. Statistical analysis was performed using R (R version 4.0.2) on a Linux station (Ubuntu 15.04).
Results
Search results
A total of 995 abstracts were screened. Of these, 978 were excluded because they were not relevant or did not meet our inclusion criteria. Finally, 17 [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] studies met the inclusion criteria and were included in this meta-analysis. Eight studies were prospective uncontrolled studies, [16] [17] [18] 22, 24, 26, 29, 31 seven were retrospective [19] [20] [21] 23, 25, 28, 30 and two were randomized controlled trials. 15, 27 Thirteen studies were single center and four were multicentric. Five studies described a cohort of both CDS and HGS with a sample size greater than 15. 15, 16, 19, 26, 28 (Table 1 ). Therefore, these 17 studies described 13 HGS patient cohorts and 10 CDS cohorts. All cases of biliary obstruction were due to malignancy. The most frequent was pancreatic cancer with 87 (30.74%) and 85 (30.04%) patients undergoing CDS and HGS, respectively ( Table 2 ). The agreement between reviewers for the collected data gave a Cohen kappa value of 1.0.
Overall clinical efficacy of EUBD technique
Thirteen studies described a hepaticogastrostomy biliary drainage technique with an overall number of 403 patients ( Figure 2 ). The overall clinical success rate was 84% CI 95% (80-88). By using the I 2 statistic, we did not find a significant heterogeneity (I 2 ¼ 19%, p ¼ 0.26). The Egger test was found to be statistically significant (p ¼ 0.018), which indicates publication bias. Nine studies described a CDS biliary drainage technique with more than 15 patients with an overall number of 283 patients. The overall clinical success rate was 87% CI 95% (82-91). By using the I 2 statistic, we did not find a significant heterogeneity (I 2 ¼ 37%, p ¼ 0.12). The Egger test was found to be statistically significant (p ¼ 0.007), which indicates publication bias (Table 3) . We could not find a significant difference between CDS and HGS (p ¼ 0.37). 
Overall technical efficacy of EUBD technique
In the pooled patient population, the percentage of patients whose HGS procedure was a technical success was 96% CI 95% (93-98) ( Figure 2 ). Heterogeneity was not significant (I 2 ¼ 0%, p ¼ 0.93). The Egger test for assessing publication bias was found to be significant (p < 0.001). The percentage of patients with a technical success after CDS was 95% CI 95 (91-97). We did not find a significant heterogeneity (I 2 ¼ 0%, p ¼ 0.9) but did find a signification publication bias (Egger test p ¼ 0.026). The test for subgroup differences found no significant difference between CDS and HGS regarding technical success (p ¼ 0.46) ( Table 3) .
Overall adverse event rate of EUBD technique
In the pooled patient population, the percentage of adverse events was 29% CI 95% (24-34) with HGS ( Figure 2 ). Heterogeneity was significant (I 2 ¼ 70%, p < 0.01). However, the Egger test showed no evidence of a publication bias (p ¼ 0.052) ( Table 3 ). The most frequently reported side events were stent dysfunction (n ¼ 34), bleeding or hemobilia (n ¼ 12) and distal migration (n ¼ 8) (Table 4 ).
The percentage of adverse events with CDS was 20% CI 95% (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . Heterogeneity was not significant (I 2 ¼ 31%, p ¼ 0.17) but we did find a significant publication bias (Egger test ¼ 0.028) and a significant subgroup difference (p ¼ 0.01) ( Table 3 ). The most frequently reported side events were stent dysfunction (n ¼ 10), peritonitis (n ¼ 7) and pneumoperitoneum (n ¼ 6) ( Table 4) .
CDS vs HDS (Figure 3)
Five studies described both HGS and CDS. 15, 16, 19, 26, 28 Compared with HGS the pooled odds ratio (OR) was 36 introduced the first EUS-guided RDV approach in two cases of obstructive jaundice due to malignancy after failed ERCP. Since then, many mostly small retrospective and prospective studies have been available and EUBD has been compared to PTBD. A recent meta-analysis 37 comparing the efficacy and safety of EUBD to PTBD found that EUBD was associated with significantly better clinical success, a lower rate of postprocedure adverse events, and fewer 15 published the first prospective randomized controlled trial comparing EUBD with PTBD. Twenty-five patients were randomized. All procedures were technically and clinically successful in both groups. There was no difference of complication rates between groups (p ¼ 0.44), CDS (2/ 13; 15.3%) and PTBD (3/12; 25%). Those results suggested that EUBD can be an effective and safe alternative to PTBD with similar success, complication rates, cost and quality of life. Another study conducted by Khashab and colleagues 19 compared the outcomes of 73 patients (22 EUBD and 51 PTBD). Technical success was higher for PTBD, but clinical success was similar, and adverse events were also higher for PTBD. Our results show that EUBD can be performed with high technical and clinical success rates but is associated with a 20% risk of adverse events. One advantage of the EUBD technique compared with PTBD is that EUBD can be performed in patients with ascitis and liver metastasis. The choice of the best approach to EUBD, i.e. essentially transgastric vs transduodenal, deserves a specific analysis.
Artifon et al. 15 reported a randomized trial comparing the outcomes of CDS and HGS in 49 patients. The technical success rate was 91% for CDS and 96% for HGS (p ¼ 0.61). Similarly, clinical success was comparable in both groups (77% vs 91%, respectively; p ¼ 0.23). The overall adverse event rate was 16.3% (CDS, 12.5%; HGS, 20%). The authors concluded that CDS and HGS techniques provide similar efficacy and safety, and both are valid options for draining distal malignant biliary obstruction after failed ERCP. In our meta-analysis, however, we did not find a significant difference in technical or clinical success rates, but adverse event rate was significantly higher with HGS compared to CDS.
EUBD is technically difficult and currently complications rates remain relatively high compared to ERCP, so only endoscopists skilled both in EUS and ERCP should perform EUS-guided biliary and pancreatic drainage procedures when ERCP cannot be achieved. It is worthy of note that all studies originated from tertiary high-volume centers that employ highly qualified interventional endoscopists. Although Vila et al. in 2012 38 could not find an association of hospital type (community vs tertiary care) with a higher technical success or complication rate, we consider the feasibility of these techniques in community hospitals needs to be evaluated.
A previous meta-analysis was conducted very recently by Uemura et al., 39 which to our knowledge is the only previously published meta-analysis comparing HGS to CDS. This study has shown similar technical and clinical efficacy for both techniques, and contrary to the present study also found no difference in the adverse events rate (OR ¼ 0.97 (0.60-1.56)). This different result could be explained by a fewer number of included studies leading to a smaller sample size and different eligibility criteria. Contrary to Uemura and colleagues, 39 we chose to include articles that describe cohorts containing at least 15 patients, which may be more representative of high-volume centers describing a large number of patients treated by an experienced clinician familiar with the technique. Also, we chose to include only studies that described both clinical and technical success as well as adverse events. Although we found more adverse events with HGS than CDS, it is noteworthy that most of those are cases of stent dysfunction (34 occurrences with HGS vs 10 with CDS), which could have a stronger relation with the type of stent used than with the technique of biliary access. It was not possible to take into account this potential confounding factor since stent types were not always detailed in the studies.
We also recognize the present meta-analysis study has several limitations. First, a significant publication bias has been found for a large part of the results. Second, most of the studies were retrospective, were not randomized or had only one arm. It is therefore difficult to compare the two drainage techniques that are performed in two different populations. Also, some interventional endoscopists might have a preferred route because of their personal experience or for anatomical reasons. HGS is the preferred route-or the only one available-in the presence of a proximal biliary stricture and/or after distal gastrectomy that prohibits access to the extrahepatic bile duct. CDS can be preferred in case of a native papilla, a dilated common bile duct and nondilated left intrahepatic ducts. Finally, studies were performed over different time periods in different countries with different equipment, populations and definitions of technical and clinical success. Because of this conceptual heterogeneity, the pooled estimate has to be interpreted cautiously.
We show in this meta-analysis and systematic review that when bile duct access cannot be obtained as a result of failed cannulation or anatomical modification, EUBD can advantageously be used as an alternative to interventional radiology or surgery. We did not find a significant difference between CDS and HGS regarding clinical and technical success, but the available literature suggests CDS is a safer approach compared to HGS. However, the above-mentioned limitations and biases in published studies warrant caution in the interpretation of this finding. Randomized controlled trials with sufficiently large cohorts are needed to compare techniques and refine these findings.
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